JP2007105268A - Stent - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a lumen stent having a sufficient strength for withstanding the expanding strength of the tubular tissue, having flexibility for advancing in a steeply curved tubular tissue and reaching a target side without any problem, uniformly covering the tubular tissue and reducing lesion to the tubular tissue when expanding the stent. <P>SOLUTION: The lumen stent is formed in an approximately tubular shape and expands from a first diameter being smaller than the inside diameter of the lumen and movable to an intended position, to a second diameter being indwelled in the lumen. This stent is characterized in that one end of a first waveform component formed of two first struts and one end of a second waveform component formed of two second struts are joined to constitute a waveform unit and the length of the second strut is longer than the length of the first strut. <P>COPYRIGHT: (C)2007,JPO&INPIT

Description

  The present invention generally relates to a stent for implantation in a living body.

  Stents are used to treat various diseases caused by stenosis or occlusion of blood vessels or other in-vivo lumens, to expand the stenosis or occlusion site and to maintain the size of the lumen. A medical device comprising a coiled stent made of a single linear metal or polymer material, a metal tube cut out and processed by a laser, and a linear member assembled by welding with a laser And those made by weaving multiple linear metals.

  These can be expanded by balloons with stents mounted (balloon expandable type), and can be expanded by removing members that suppress expansion from outside (self-expandable type). Can be classified. The balloon expandable type is attached to the balloon portion of an expandable member (balloon catheter) attached to the vicinity of the distal end of the intravascular catheter (balloon catheter), and advances the catheter to the treatment site in the body lumen of the patient. The balloon is inflated at the treatment site, and the stent is expanded and indwelled accordingly. The balloon is then deflated and the catheter is removed. When the balloon is expanded, the expansion pressure is adjusted according to the state of the tubular tissue to be expanded and the mechanical strength of the stent.

  In recent years, these stents have been frequently used especially for angioplasty of the heart, carotid artery and lower limb artery, and it has been shown that the frequency of restenosis is significantly reduced by stent placement. However, the current situation is that it still causes restenosis with a high probability. For example, regarding the cardiac coronary artery, even when stenting is performed, the occurrence of restenosis has been reported with a frequency of about 20 to 30%. This restenosis may be induced from biological vascular injury or vascular injury due to stent placement. It is considered that typical vascular stenosis and restenosis induced by vascular injury is caused by proliferation of intimal smooth muscle cells. First, smooth muscle cells start to grow following vascular injury, and then the smooth muscle cells migrate to the intima. Smooth muscle cells in the intima then proliferate with matrix deposition resulting in intimal thickening. T cells, macrophages and the like are also considered to migrate to the intima.

In order to solve these problems, various stent designs (geometric shapes) have been proposed, which are capable of developing strength that is comparable to the tubular tissue to be expanded. We have been aiming to improve performance such as those that have the flexibility to advance to the target site without problems, those that can cover the tubular tissue more uniformly, and those that have less damage to the tubular tissue when the stent is expanded. These are disclosed in Patent Document 1 and Patent Document 2, for example. For example, in Patent Document 1, a cell formed into a rectangle before expansion has a rhombus or hexagonal cell shape after expansion, and each vertex of the cell is arranged in the circumferential direction, so that elastic deformation is allowed. Without design, it is designed to ensure strength after expansion. Therefore, since there is no elastic deformability, it is difficult to obtain flexibility. Further, for example, in Patent Document 2, a rhombus cell is connected in the circumferential direction, and adjacent cells in the longitudinal direction are connected by a curved connection strut, which is proposed as a cell design having indirectness. . In this example, it has a design for obtaining flexibility, but it is difficult to ensure strength at the indirect portion for obtaining flexibility.
Furthermore, for example, Patent Document 3 proposes an attempt to reduce the restenosis rate by coating a stent with a drug that restricts occlusion. Numerous drugs such as anticoagulants, antiplatelet substances, antispasmodics, antibacterial drugs, antitumor drugs, antimicrobials, anti-inflammatory drugs, antimetabolites, and immunosuppressive drugs have been studied as drugs that limit obstruction. Yes. With regard to immunosuppressive agents, attempts have been proposed to coat stents with cyclosporine, tacrolimus (FK-506), sirolimus (rapamycin), mycophenolate mofetil, and their analogs to further reduce restenosis, For example, Patent Document 4 discloses a stent coated with tacrolimus (FK-506).

  As mentioned so far, it has sufficient strength not to be defeated by the tubular tissue to be expanded, has flexibility to be able to advance through the severely bent tubular tissue and advance to the target site without problems, tubular It can cover the tissue uniformly, can reduce damage to the tubular tissue when the stent is expanded, can be applied to the stent coated with the drug, and can apply a sufficient amount of the drug as much as possible, and evenly distribute the drug to the intraluminal tissue It has been required as a problem in the prior art to be able to be released and to have a retention force of the stent and balloon so that the stent can be safely advanced into the patient body cavity.

In addition, it has been found that reducing the diameter of the stent during insertion to reduce damage to the blood vessel during insertion into the blood vessel is less invasive, but the stent is expanded for implantation. In this case, the expansion width from the first diameter to the second diameter is increased, and an excessive load is applied to the deformation of the stent, and the strength of the stent is lowered after the expansion. Therefore, the prior art cannot reduce the diameter of the stent beyond a certain level.
Japanese Patent Application Publication Gazette No. 4-6377 Japanese Patent Application Publication No. 11-501551 Japanese Patent Application Publication Gazette Japanese Patent Application Laid-Open No. 5-502179 European Patent Publication No. 12554674

  In view of these circumstances, the present invention intends to solve the problem that it has sufficient strength not to be defeated by the tubular tissue to be expanded, and can proceed through the severely bent tubular tissue without difficulty to the target site. It is an object of the present invention to provide an intravascular stent which has flexibility that can be applied, can uniformly cover the tubular tissue, and can reduce damage to the tubular tissue when the stent is expanded. Another problem to be solved is to provide an endovascular stent that can apply as much and sufficient amount of drug as possible on the drug-coated stent and can uniformly release the drug to the intraluminal tissue. Yet another problem to be solved is to provide an endovascular stent that can have a stent and balloon retention force that allows the stent to be safely advanced into the patient's body cavity. Yet another problem to be solved is to provide an intravascular stent having a smaller outer diameter before expansion of the stent and sufficient strength of the stent after expansion.

Thus, the present invention provides:
(1)
An intraluminal stent formed in a generally tubular body and expanding from a first diameter that is smaller than a lumen inner diameter and movable to a desired position to a second diameter that can be placed in the lumen;
One end of the first corrugated component consisting of two first struts and one end of the second corrugated component consisting of two second struts are connected to form a waveform unit,
Here, the length of the second strut is longer than the length of the first strut,
The corrugated unit is adjacent to the longitudinal direction of the tubular body, and the apex of the first corrugated component of one corrugated unit and the apex of the second corrugated component of the other corrugated unit are the longitudinal direction of the substantially tubular body. Connected to the stent segment,
A stent characterized by that.
(2)
The stent segment is adjacent in the circumferential direction of the generally tubular body, the end of the first corrugation component of the first corrugation unit of one stent segment, and the second corrugation component of the second corrugation unit of the other stent segment The stent according to (1), wherein the end of each is connected in the circumferential direction of the substantially tubular body.
(3)
The stent segment is adjacent in the circumferential direction of the generally tubular body, the end of the first corrugation component of the first corrugation unit of one stent segment, and the first corrugation component of the second corrugation unit of the other stent segment The stent according to (1) or (2), wherein the end of each is connected in the circumferential direction of the substantially tubular body.
(4)
The stent segment is adjacent to the longitudinal direction of the generally tubular body, and the end of the first corrugated component of one stent segment and the end of the first corrugated component of the other stent segment are the generally tubular body. The stent according to any one of (1) to (3), which is connected in the longitudinal direction.
(5)
The stent segment is adjacent to the longitudinal direction of the generally tubular body, and the end of the first corrugated component of one stent segment and the end of the second corrugated component of the other stent segment are the generally tubular body. The stent according to any one of (1) to (4), which is connected in the longitudinal direction.
(6) The stent according to any one of (1) to (5), wherein the length of the second strut is 1.2 to 2.5 times the length of the first strut.
(7)
The material forming the stent includes one or more of the group consisting of iron, chromium, nickel, cobalt, aluminum, molybdenum, manganese, titanium, tantalum, niobium, tungsten, copper, silver, gold and platinum (1) to ( 6) Any endovascular stent.
(8)
The intravascular stent according to any one of (1) to (6), wherein a drug that suppresses occlusion is immobilized on the stent surface.
(9)
The stent according to (8), wherein the drug is immobilized on the surface of the stent in the form of a mixture with a biocompatible polymer.
(10)
The stent according to (8), wherein the drug is immobilized on the surface of the stent in the form of a mixture with a biodegradable polymer.
I will provide a.

  According to the present invention (1), it has at least two types of corrugated elements, the first corrugated component is shorter than the second corrugated component, contributes to maintaining the strength of the stent in the expanded state, and The second corrugated component is longer than the first corrugated component, and ensures a large amount of deformation during expansion. By combining these two types of components in a certain pattern, the first diameter before expansion is expanded from the first diameter. It is possible to maintain the strength of the stent while increasing the expansion width for expanding to the second diameter of the stent, and when the stent is inserted into the blood vessel before expansion, and the position where the stent is desired in the blood vessel. It is in the point that a technique can be performed with minimal invasiveness when moving up to.

  Yet another advantage is that when the at least two types of corrugated components are combined, when the stent is expanded, the cells of the combined stent do not consist solely of cells that form diamonds. As for the stent cell shape, cells forming at least a parallelogram and cells forming a wedge shape and / or cells forming a rhombus are arranged in a certain pattern, so that the parallelogram cell is elastically deformed by sliding. As a result, the wedge-shaped and / or diamond-shaped cell elastically inhibits deformation and secures the radial strength when the stent is expanded. This combination has a high expansion width, is flexible, and can have high strength in the radial direction.

Another effect is that the apex of each cell is connected to the apex of the adjacent cell, increasing the strength, and part of the cell warps when the blood vessel is bent due to a bent blood vessel or external pressure. Since it can be prevented from going up, damage to the blood vessel can be suppressed even after placement of the blood vessel.
Furthermore, according to the present invention (2), the strut lengths are alternately long and short in the circumferential direction, and the radial strength is particularly good.
Furthermore, according to the present invention (3), since the strut length is continuous every two units in the circumferential direction, the radial strength is reduced as compared with the present invention (2), but the flexibility is particularly good.
Furthermore, according to the present invention (4), two types of large and small rhombus, wedge-shaped, and parallelogram cells are formed, and a long strut flexibly deforms from a small rhombus with high strength, and against external force. Have flexibility.
Furthermore, according to the present invention (5), wedge-shaped and parallelogram-shaped cells are formed, and the overall length of the formed cells is uniform, so that the strength in the radial direction is uniform over the length direction. And good strength.
Further, according to the present invention (6), the length of the second strut is not less than 1.2 times and not more than 2.5 times the length of the first strut. Long and short struts can complement each other's characteristics while long struts ensure flexibility. Conversely, if the length of the second strut is less than 1.2 times the length of the first strut, the length of the short and short struts hardly changes and it is difficult to obtain flexibility. In addition, when the length of the second strut is larger than 2.5 times the length of the first strut, the long strut alone is deformed without being interfered with the short strut, thereby ensuring strength. It becomes difficult.
Furthermore, according to the present invention (7) to (10), in a stent coated with a drug, the drug can be uniformly released to an intraluminal tissue.

Hereinafter, embodiments of the stent according to the present invention will be described, but the present invention is not limited thereto.
An embodiment of the present invention is an intravascular stent for implantation into a body lumen, which is formed in a substantially tubular body, and is placed in a tube from a first diameter that is smaller than the inner diameter of the tube and can be moved to a desired position. An endovascular stent that expands to a possible second diameter, one end of a first corrugated component comprising two first struts and one end of a second corrugated component comprising two second struts Are connected to each other to form a corrugated unit, wherein the length of the second strut is longer than the length of the first strut, and the corrugated unit is adjacent to the longitudinal direction of the tubular body, The apex of the first corrugated component of the corrugated unit and the apex of the second corrugated component of the other corrugated unit are connected in the longitudinal direction of the substantially tubular body to form a stent segment, whereby the first The waveform when expanded to a diameter of 2 The shape of the cell formed from the component does not consist only of cells that form a rhombus, and the stent cell shape forms a cell that forms at least a parallelogram, a cell that forms a wedge shape, and / or a rhombus Cells to be lined up in a certain pattern.
A strut is a term indicating a part constituting a stent, and a stent is composed of various struts (for example, a bent strut, a straight strut, a corrugated strut, a sine wave shaped strut).

  In the form of the present invention, there are two types of struts, long and short, and when the stent is expanded from the compressed first diameter to the expanded second diameter, The expansion width from one diameter to the second diameter can be substantially increased compared to a conventional stent. Thereby, since the larger expansion can be performed, the first diameter before the expansion can be reduced, and the degree of damage to the tissue can be reduced with less invasiveness. Further, by fixing the drug on the surface of the stent of the present invention by dipping or coating, it becomes possible to release the drug to the tissue more uniformly.

  Depending on the size of other devices to be combined with this stent, for example, from the viewpoint of treating a lower limb artery, the compressed first diameter is set to be 3.0 mm or less, preferably 2.5 mm or less. . The first diameter is preferably as small as possible, but can be 1.2 mm or more from the viewpoint of manufacturing. The expanded second diameter is selected according to the inner diameter of the patient body lumen, and is completely different depending on the lumen to be treated. For example, when the lower limb artery is taken as an example, the diameter is set to about 6.0 mm to 12.0 mm.

  As a method for forming a stent, a laser processing method, an electric discharge processing method, a mechanical cutting method, an etching method, and the like that are generally known as methods for producing a stent can be used. Further, it is generally known to those skilled in the art to chamfer the end portions of the struts in various types of polishing such as electrolytic polishing after forming the stent, and can also be applied to the present invention.

  The stent according to the present invention can be made of metal such as stainless steel, Ni-Ti alloy, Cu-Al-Mn alloy, Co-Cr alloy, etc. having appropriate rigidity and elasticity. For example, in JIS-G4303 The metal prescribed | regulated or the metal prescribed | regulated by ISO5832-5, ISO5832-6, ISO5832-7, etc. can be used.

  The stent shape (geometric shape) which is one of the embodiments of the present invention is a cylindrical loop element that is radially expandable, and these cylindrical loop elements are formed substantially continuously in the axial direction. A stent.

  The present invention can immobilize, for example, immerse or apply a drug that inhibits occlusion on a stent surface, such as vinca alkaloids (ie, vinblastine, vincristine and vinolerubin), paclitaxel, epidipodophyllotoxin Anti-proliferation / anti-mitotic agents including natural products such as etoposide, teniposide; dactinomycin (actinomycin D), daunorubicin, doxorubicin and idarubicin, anthracycline, mitoxantrone, bleomycin, priomycin (mitromycin) And antibiotics such as mitomycin; enzymes (such as L-asparaginase that systematically metabolizes L-asparagine and are not found in cells without the ability to synthesize asparagine); nitrogen mustard (mechlorethamine, cyclophor Famide and its analogues, melphalan, chlorambucil, etc.), ethyleneimine and methylmelamine (such as hexamethylmelamine and thiotepa), busulfan alkyl sulfate, nitrosourea (such as carmustine (BCNU) and analogues, streptozocin, etc.), trazen-dacarbazinine Anti-proliferative / anti-mitotic alkylating agents such as (DTIC); folic acid analogues (such as methotrexate), pyrimidine analogues (such as fluorouracil, floxuridine and cytarabine), purine analogues and related inhibitors (mercaptopurine, thioguanine) Antiproliferative / antimitotic antimetabolites such as pentostatin and 2-chlorodeoxyadenosine {Cladribine}); platinum coordination complexes (cisplatin, carboplatin, etc.), procarbazine, hydroxyurea, Totanes, aminoglutethimides; hormones (ie estrogens, etc.); anticoagulants (such as heparin, synthetic heparin salts and other thrombin inhibitors); fibrinogen degrading agents (such as tissue plasminogen activator, streptokinase and urokinase) Antiplatelet agents (aspirin, dipyridamole, ticlopidine, clopidogrel, abciximab, etc.); transition inhibitors; secretion inhibitors (bravezine, etc.); corticosteroids (cortisol, cortisone, fludrocortisone, prednisone, prednisolone, 6α-methylprednisolone, Anti-inflammatory agents such as triamcinolone, betamethasone and dexamethasone), non-steroidal agents (such as salicylic acid derivatives, ie, aspirin); para-aminophenol derivatives, ie, acetami Phen; indole and indene acetic acid (such as indomethacin, sulindac and etodalac), heteroaryl acetic acid (such as tolmethine, diclofenac and ketorolac), arylpropionic acid (such as ibuprofen and derivatives), anthranilic acid (such as mefenamic acid and meclofenamic acid), enolic acid (Such as piroxicam, tenoxicam, phenylbutazone and oxyfentatrazone), nabumetone, gold compounds (such as auranofin, aurothioglucose, gold sodium thiomalate); immunosuppressants (cyclosporine, tacrolimus (FK-506), sirolimus (Rapamycin), azathioprine, mycophenolate mofetil, everolimus, ABT-578, CCI-779, AP23573, etc.); angiogenic agent: intravascular Growth factor (VEGF), fibroblast growth factor (FGF); nitric oxide donors; such as an antisense oligonucleotide, and can be selected from combinations thereof.

  As a method of fixing the drug to the stent, there are a method of physically fixing the drug and a method of fixing a biocompatible polymer as a binder. As a coating method, a method of dipping a stent into a solution, a method of spraying by a spray, or the like can be performed.

  As the biocompatible polymer used in the present invention, any biocompatible polymer can be used as long as it does not substantially adhere to platelets, shows no irritation to tissues, and can be eluted. However, for example, synthetic polymers may include polyether-type polyurethane and dimethylsilicone blends or block copolymers, polyurethanes such as segmented polyurethane, polycarbonates such as polyacrylamide, polyethylene oxide, polyethylene carbonate, and polypropylene carbonate. Fibrin, gelatin, collagen, etc. can be used as the natural biocompatible polymer. These polymers can be used alone or in appropriate combination. The biodegradable polymer used in the present invention is any biodegradable polymer as long as it is enzymatically or non-enzymatically degraded in the living body, the degradation product does not exhibit toxicity, and the drug can be released. Is also available. For example, polylactic acid, polyglycolic acid, a copolymer of polylactic acid and polyglycolic acid, collagen, gelatin, chitin, chitosan, hyaluronic acid, poly-L-glutamic acid, poly-L-lysine and other polyamino acids, starch, A material appropriately selected from poly-ε-caprolactone, polyethylene succinate, poly-β-hydroxyalkanoate and the like can be used. These polymers can be used alone or in appropriate combination.

  One embodiment of the present invention will be described with reference to the drawings, but the present invention is not limited thereto.

  FIG. 1 shows an embodiment of a unit in which a first waveform component and a second waveform component according to the present invention are combined. The strut length of the second corrugated component may be longer than the strut length of the first corrugated component. From the viewpoint of the radial strength after expansion, the strut length of the second corrugated component is preferably 1.2 times or more and 2.5 times or less than the strut length of the first corrugated component. In the embodiment of FIG. 1, the strut length of the second corrugated component is shown as 1.5 times the strut length of the first corrugated component.

FIG. 2 shows an embodiment of a segment in which the units according to the invention are alternately facing and connected at the apex.
3 and 4 show an embodiment as an example of a stent according to the present invention. FIG. 3 shows a development view when the stent of the embodiment is contracted. Thus, in an embodiment, when the stent is fixed to the catheter or balloon, the segments are connected in the circumferential direction and have a certain pattern. FIG. 4 shows a development view of the embodiment when the stent is expanded. After expansion, the long struts do not hinder expansion, so that a large expansion width can be obtained. Further, the expanded cell is composed of a combination of a parallelogram cell and a wedge-shaped cell. For this reason, when an external force is applied, the parallelogram cell mechanically undergoes elastic deformation, and when the external force is removed, it easily returns to its original shape. Therefore, it has flexibility even after expansion.
The stent of the embodiment was made using a metal (cobalt chromium alloy) specified in ISO5832-6. The strut width was 140 μm, the thickness was 70 μm, and the stent length was 13 mm. In an embodiment, the stent was coated with a biocompatible polymer and an agent that suppresses occlusion. The biocompatible polymer uses a polylactic acid polyglycolic acid copolymer (SIGMA, lactic acid / glycolic acid = 85/15, weight average molecular weight 90,000-126,000), which is also a biodegradable polymer. Tacrolimus (FK506) known as an immunosuppressive agent was used as the suppressive agent. Tacrolimus (FK506) is a compound having CAS number 104987-11-3, and is disclosed, for example, in JP-A-61-148181. Tacrolimus (FK506) forms a complex with intracellular FK506 binding protein (FKBP) and is thought to inhibit the production of cytokines such as IL-2 and INF-γ, which are differentiation / proliferation factors, from T cells. It is known that it can be used as a preventive or therapeutic agent for rejection at the time of organ transplantation and autoimmune diseases. A copolymer of polylactic acid and polyglycolic acid and tacrolimus were dissolved in chloroform to prepare solutions each having a concentration of 0.5 wt%, and were applied by brushing the portions to be coated.

As another embodiment according to the present invention, an example of a stent is shown in FIGS. FIG. 5 shows a development view of the embodiment when the stent is contracted. Thus, in an embodiment, when the stent is fixed to the catheter or balloon, the segments are connected in the circumferential direction and have a certain pattern. FIG. 4 shows a development view of the embodiment when the stent is expanded. After expansion, the long struts do not hinder expansion, so that a large expansion width can be secured. Further, the expanded cell is constituted by a parallelogram cell, a wedge-shaped cell, and a diamond-shaped cell. The stent of the embodiment was made using a metal (nickel-titanium alloy) specified in ISO5832-5. The strut width was 230 μm, the thickness was 100 μm, and the stent length was 30 mm.
(Comparative example)
11 and 12 show a comparative example. FIG. 11 is a development view of a conventional stent when contracted. From this figure, the conventional stent has a single strut length of the corrugated component. FIG. 12 is a development view of the comparative example 1 when it is expanded. It can be seen from the expanded view of Comparative Example 1 that the expanded cells all have diamond shapes. For this reason, if the expansion width is increased, the struts are completely opened, and it becomes difficult to maintain the shape after expansion. Moreover, since all are rhombuses, when an external force is applied, mechanical elastic deformation cannot be caused, and when an external force greater than the radial force is applied, plastic deformation occurs.

The stent unit which combined the 1st waveform component and 2nd waveform component which concern on this invention. The stent segment which combined the stent unit which concerns on this invention. The expanded view in the contracted state of the stent which is the embodiment which concerns on this invention. This corresponds to the present invention (2). The expanded view in the expansion state of the stent which is the embodiment which concerns on this invention. This corresponds to the present invention (2). The expanded view in the contracted state of the stent which is the embodiment which concerns on this invention. This corresponds to the present invention (3). The expanded view in the expansion state of the stent which is the embodiment which concerns on this invention. This corresponds to the present invention (3). The expanded view in the contracted state of the stent which is the embodiment which concerns on this invention. This corresponds to the present invention (4). The expanded view in the expansion state of the stent which is the embodiment which concerns on this invention. This corresponds to the present invention (4). The expanded view in the contracted state of the stent which is the embodiment which concerns on this invention. The expanded view in the expansion state of the stent which is the embodiment which concerns on this invention. The expanded view in the contracted state of the comparative example 1. FIG. The expanded view in the expansion state of the comparative example 1. FIG.

Explanation of symbols

DESCRIPTION OF SYMBOLS 10 First waveform component 11 First waveform component strut 20 Second waveform component 21 Second waveform component strut

Claims (10)

An intraluminal stent formed in a generally tubular body and expanding from a first diameter that is smaller than a lumen inner diameter and movable to a desired position to a second diameter that can be placed in the lumen;
One end of the first corrugated component consisting of two first struts and one end of the second corrugated component consisting of two second struts are connected to form a waveform unit,
Here, the length of the second strut is longer than the length of the first strut,
The corrugated unit is adjacent to the longitudinal direction of the tubular body, and the apex of the first corrugated component of one corrugated unit and the apex of the second corrugated component of the other corrugated unit are the longitudinal direction of the substantially tubular body. Connected to the stent segment,
A stent characterized by that. The stent segment is adjacent in the circumferential direction of the generally tubular body, the end of the first corrugation component of the first corrugation unit of one stent segment, and the second corrugation component of the second corrugation unit of the other stent segment The stent according to claim 1, wherein the end of the stent is connected in the circumferential direction of the substantially tubular body. The stent segment is adjacent in the circumferential direction of the generally tubular body, the end of the first corrugation component of the first corrugation unit of one stent segment, and the first corrugation component of the second corrugation unit of the other stent segment 3. The stent according to claim 1, wherein the end of the stent is connected in a circumferential direction of the substantially tubular body. The stent segment is adjacent to the longitudinal direction of the generally tubular body, and the end of the first corrugated component of one stent segment and the end of the first corrugated component of the other stent segment are the generally tubular body. The stent according to any one of claims 1 to 3, wherein the stent is connected in the longitudinal direction. The stent segment is adjacent to the longitudinal direction of the generally tubular body, and the end of the first corrugated component of one stent segment and the end of the second corrugated component of the other stent segment are the generally tubular body. The stent according to any one of claims 1 to 4, wherein the stent is connected in the longitudinal direction. The stent according to any one of claims 1 to 5, wherein a length of the second strut is 1.2 times or more and 2.5 times or less of a length of the first strut.   The material forming the stent includes one or more of the group consisting of iron, chromium, nickel, cobalt, aluminum, molybdenum, manganese, titanium, tantalum, niobium, tungsten, copper, silver, gold and platinum. Any endovascular stent. The intravascular stent according to any one of claims 1 to 6, wherein a drug for suppressing occlusion is immobilized on the surface of the stent. The stent of claim 8, wherein the agent is immobilized on the stent surface in the form of a mixture with a biocompatible polymer. The stent of claim 8, wherein the drug is immobilized on the stent surface in the form of a mixture with a biodegradable polymer.